Last reviewed · How we verify

NCT06875544: Randomized

Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation Randomized Controlled Trail

Not yet recruiting NA Last updated 8 March 2025
What this trial tests

NA trial testing Beautifil F00 in DME in 50 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
1 April 2026
1 April 2026

Quick facts

Lead sponsorFuture University in Egypt
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingdouble
Primary purposetreatment
Enrollment50
Start date1 March 2025
Primary completion1 April 2026
Estimated completion1 April 2026

Drugs / interventions tested

Conditions studied

Sponsor

Future University in Egypt

Who can join

Adults 20 to 50, any sex, with DME or Dental. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Using a bioactive resin composite in subgingival Class II cavities can provide enhanced caries resistance by releasing multiple ions, including fluoride. This approach offers greater resistance to caries due to the incorporation of surface pre-reacted glass filler (S-PRG) technology (Imazato, Nakatsuka et al., 2023). This type of composite may improve the outcomes of deep subgingival margin elevation, benefiting both restorative success and periodontal health.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Future University in Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing